questions // answered straight
CJC-1295 Ipamorelin: Questions, Answered
Direct answers to what people actually search, each cited where it makes a number claim.
Does CJC-1295 / Ipamorelin work?
In the sense of raising growth hormone, yes — and it is measured. A single subcutaneous dose of CJC-1295 (DAC) raised mean plasma GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults; after multiple doses IGF-1 stayed above baseline up to 28 days [1]. "Works" for downstream body-composition goals in humans is extrapolated, not proven for the blend.
How does CJC-1295 / Ipamorelin work?
Two switches on the same pituitary cells. CJC-1295 binds the GHRH receptor (raising cAMP) and ipamorelin binds the ghrelin receptor, GHS-R1a (raising calcium) — independent pathways [2][5]. Co-activating both produced roughly twice the cAMP of GHRH alone in transfected cells [4], so the combined GH pulse is larger than either arm's alone [3].
Can you take both Sermorelin and Ipamorelin together?
Mechanistically they are the two complementary arms of a synergy stack — sermorelin is a GHRH analogue, ipamorelin a GHRP. In normal men, submaximal GHRP doses (0.1 and 0.3 µg/kg) combined with GHRH (1 µg/kg) stimulated GH release synergistically through independent mechanisms [3]. That said, no controlled trial has tested this specific fixed combination, and nothing here is dosing guidance.
Can you take CJC-1295 / Ipamorelin and Tesamorelin together?
Tesamorelin is itself a GHRH analogue, so combining it with CJC-1295 (also a GHRH analogue) would double the same arm rather than add a complementary one. The studied synergy is GHRP + GHRH: submaximal GHRP plus GHRH stimulated GH release synergistically via independent mechanisms [3]. No trial has tested a tesamorelin + CJC-1295/ipamorelin combination, and this is not a protocol.
Can you take CJC-1295 / Ipamorelin and Sermorelin together?
Sermorelin and the CJC-1295 half are both GHRH analogues — stacking them stacks the same arm. The synergy that the literature supports is between a GHRH analogue and a GHRP (ipamorelin): in normal men, GHRP plus GHRH produced supra-additive GH release through independent mechanisms [3]. No controlled study has evaluated this exact combination; nothing here is dosing advice.
Does CJC-1295 / Ipamorelin increase testosterone?
The studied effect is on growth hormone and IGF-1, not testosterone. A single CJC-1295 (DAC) dose raised GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults [1]. The published literature on this stack does not demonstrate a direct increase in testosterone; claims to that effect are not supported by the cited data.
What is CJC-1295 / Ipamorelin good for?
In research terms, it is studied as a way to raise the body's own growth-hormone output via two complementary receptors. The measured outcome is GH and IGF-1 elevation: 2- to 10-fold GH and 1.5- to 3-fold IGF-1 from a single CJC-1295 dose [1]. Reported downstream effects (sleep, recovery, body composition) are anecdotal for the combination — see the effects page.
What are the bad side effects of CJC-1295 and Ipamorelin?
Ipamorelin's defining trait is that it is selective: unlike GHRP-6 and GHRP-2 it did not raise ACTH or cortisol above GHRH-stimulated levels even at doses over 200× the GH-releasing dose [2]. Across the GHS class, the chief concern is increased blood glucose from reduced insulin sensitivity [6]. Community-reported effects include water retention, injection-site reactions, flushing, and tingling — anecdotal, on the effects page.
How long do CJC-1295 and Ipamorelin take to work?
On the hormone level, fast: ipamorelin's peak GH response is around 40 minutes post-dose, and a single CJC-1295 (DAC) dose raised GH for six or more days and IGF-1 for 9–11 days [1]. On the experiential level, community reports of sleep and recovery changes are described within one to two weeks and body-composition shifts from around week five — anecdotal, not clinical, and not proven for the blend.
How many mg of CJC-1295 and Ipamorelin should I take?
This site does not provide a human dose, and no validated human dose for the combination exists. Published research used CJC-1295 at 30–90 µg/kg subcutaneous in healthy adults [1] and ipamorelin at various rodent doses (e.g. 100 µg/kg three times daily) [2] — reported strictly as study data for which species and route, never as a recommendation to follow.
Does CJC-1295 raise testosterone?
CJC-1295 is a GHRH analogue; its measured action is on growth hormone and IGF-1, not testosterone. A single subcutaneous dose raised GH 2- to 10-fold for six or more days and IGF-1 1.5- to 3-fold for 9–11 days in healthy adults [1]. The cited literature does not establish a direct effect on testosterone.
Does Ipamorelin reduce belly fat?
No human trial of ipamorelin or this stack shows that. The closest evidence is for a different GHRH analogue: a 2026 meta-analysis of tesamorelin found significant reductions in visceral adipose tissue (−27.71 cm²) and hepatic fat (−4.28%) [7]. Notably, ipamorelin showed a GH-independent adipogenic (fat-promoting) effect in GH-intact mice, which complicates a simple fat-loss story.
What are the downsides to CJC-1295 / Ipamorelin?
Beyond the reported nuisances (water retention, injection-site reactions, flushing), the real downsides are evidential: neither component is FDA-approved, the fixed blend has never been tested in a controlled trial, and the chief class metabolic concern is raised blood glucose from reduced insulin sensitivity [6]. Elevating GH/IGF-1 also carries a theoretical oncologic concern, since IGF-1 is proliferative [1].
Which is better, Sermorelin or Ipamorelin?
They are not interchangeable, so "better" depends on the role. Sermorelin is a GHRH analogue (the same arm as CJC-1295); ipamorelin is a selective GHRP working a different receptor [2]. They are complementary, not competing — the synergy that raises GH most is a GHRH analogue plus a GHRP combined [3], which is exactly what this stack is.
Is Tesamorelin better than Ipamorelin?
Tesamorelin has far stronger human outcome data — a 2026 meta-analysis of 5 RCTs found significant visceral-fat (−27.71 cm²) and hepatic-fat (−4.28%) reduction with no serious adverse events [7] — but it is a GHRH analogue, a different mechanism from the GHRP ipamorelin. They are not the same class, and ipamorelin has no comparable controlled human efficacy trial.
Is Ipamorelin stronger than Sermorelin?
"Stronger" is hard to compare across mechanisms — ipamorelin (a GHRP) and sermorelin (a GHRH analogue) act on different receptors. Ipamorelin matched GHRP-6's GH efficacy in swine while being selective enough to spare the cortisol axis even above 200× the GH-releasing dose [2]. The point of the stack is that a GHRP and a GHRH analogue combined exceed either alone [3].
Which is safer, Sermorelin or Ipamorelin?
Neither has a controlled long-term human safety database, so a clean ranking is not available. Ipamorelin's notable safety feature is selectivity: it did not raise ACTH or cortisol above GHRH-stimulated levels even at very high doses [2]. Across the secretagogue class, the shared metabolic concern is raised blood glucose from reduced insulin sensitivity [6], and long-term cancer/mortality data are still needed.
Is Ipamorelin stronger than Sermorelin or comparable to it?
Because they hit different receptors, the useful answer is mechanistic, not a single ranking: ipamorelin (GHRP) and sermorelin (GHRH analogue) are complementary arms. Ipamorelin matched older GHRP GH efficacy while sparing the cortisol axis [2]; the maximal GH response in the literature comes from combining a GHRH analogue with a GHRP, not from either alone [3].
What is CJC-1295 / Ipamorelin?
A research combination of two peptides: CJC-1295, a long-acting GHRH analogue, and ipamorelin, a selective ghrelin-receptor GHRP. Together they are a growth-hormone-secretagogue "stack" — they prompt the pituitary to release more of the body's own GH via two independent receptors [2][5]. Neither is FDA-approved, and the fixed blend has never been tested in a controlled trial.
How much CJC-1295 / Ipamorelin should I take?
There is no human dose provided here and no validated human dose for the combination. The published research used CJC-1295 at 30–90 µg/kg subcutaneous in healthy adults [1]; ipamorelin doses come almost entirely from rodent models [2]. These are reported as study data for documentation — which species, which route — never as instructions.
Is CJC-1295 / Ipamorelin safe?
There is no controlled human safety trial of the combination, so "safe" cannot be asserted. Ipamorelin's class-favorable feature is selectivity — no rise in ACTH/cortisol above GHRH-stimulated levels even above 200× the GH-releasing dose [2]. The class review calls these compounds generally well tolerated short-term but flags raised blood glucose and missing long-term data [6].
Is Ipamorelin FDA approved?
No. Neither ipamorelin nor CJC-1295 is FDA-approved for any indication; both are sold only as research chemicals. A GH-secretagogue review found the class well tolerated overall, with the chief concern being increased blood glucose from decreased insulin sensitivity and long-term cancer/mortality data still needed [6]. Both are also WADA-prohibited at all times under Section S2.
How to reconstitute CJC-1295 / Ipamorelin (5mg)?
In laboratory-handling terms only: lyophilised peptide is reconstituted with bacteriostatic water (sterile water with 0.9% benzyl alcohol), then kept refrigerated at 2–8 °C, avoiding agitation and repeated freeze-thaw, since aqueous peptide degrades over weeks via deamidation. This describes the documented stability profile — not an administration instruction, and no human use is endorsed.